Answers are grounded in this paper and cite their sources.
Phase 2 trial demonstrates the potential of efgartigimod in Sjögren’s disease, suggesting a need for further studies.
Data from the RHO study support proof of concept for efgartigimod in SjD. Further evaluation in a phase 3 study of efgartigimod in individuals with SjD is warranted. The trial was registered with ClinicalTrials.gov (NCT05817669).
No takes yet. Share an insight, caveat, or question.
Peene et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: